Provided by Tiger Fintech (Singapore) Pte. Ltd.

Imunon, Inc.

0.8357
-0.0519-5.85%
Post-market: 0.83700.0013+0.16%19:06 EDT
Volume:1.02M
Turnover:868.79K
Market Cap:17.80M
PE:-0.60
High:0.9099
Open:0.8950
Low:0.8000
Close:0.8876
Loading ...

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

GlobeNewswire
·
21 Apr

IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer…

Zacks Small Cap Research
·
28 Mar

Imunon Price Target Maintained With a $14.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Mar

Imunon Is Maintained at Buy by D. Boral Capital

Dow Jones
·
24 Mar

Imunon Inc: Currently Initiating Trial Sites and Working With Trial Investigators to Begin Enrolling Study Participants

THOMSON REUTERS
·
24 Mar

Imunon Finalizes Phase 3 Study Design With FDA for Imnn-001 in Newly Diagnosed Advanced Ovarian Cancer

THOMSON REUTERS
·
24 Mar

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

GlobeNewswire
·
24 Mar

IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025…

Zacks Small Cap Research
·
28 Feb

Q4 2024 Imunon Inc Earnings Call

Thomson Reuters StreetEvents
·
28 Feb

Imunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial Challenges

GuruFocus.com
·
28 Feb

Imunon, Inc. Earnings Call: Clinical Success Amid Financial Challenges

TIPRANKS
·
28 Feb

Imunon Is Maintained at Buy by D. Boral Capital

Dow Jones
·
28 Feb

Imunon Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

Imunon FY 2024 GAAP EPS $(1.62) Beats $(1.69) Estimate. Cash And Equivalents $5.9M

Benzinga
·
27 Feb

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

GlobeNewswire
·
27 Feb

Imunon announces new analyses of results from Phase 1 trial of IMNN-101

TIPRANKS
·
26 Feb

Imunon Inc - Imnn-101 Induces 2- to 4-Fold Increase in Nab Titers

THOMSON REUTERS
·
26 Feb

Imunon Inc - Imnn-101 Shows Acceptable Safety Profile

THOMSON REUTERS
·
26 Feb

Imunon Announces New Immunogenicity Data From Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of Covid-19

THOMSON REUTERS
·
26 Feb

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

GlobeNewswire
·
26 Feb